The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations

Vaccine

Volumn 34, Issue 25, 2016, Pages 2834-2840

  Frasca, Daniela ^a   Diaz, Alain ^a   Romero, Maria ^a   Blomberg, Bonnie B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Antibody responses; Influenza vaccine; Memory B cells

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; C REACTIVE PROTEIN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; PRDM1 PROTEIN, HUMAN; REPRESSOR PROTEIN; VIRUS ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; MALE; MEMORY CELL; MIDDLE AGED; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMABLAST; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS STRAIN; YOUNG ADULT; AGED; B LYMPHOCYTE; BLOOD; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA, HUMAN; METABOLISM; PLASMA CELL;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PLASMA CELLS; REPRESSOR PROTEINS;

EID: 84964840120     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.04.023     Document Type: Article

References (39)

1. Ferrucci L., Guralnik J.M., Pahor M., Corti M.C., Havlik R.J. Hospital diagnoses, medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA 1997, 277:728-734.
2. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-1169.
3. McElhaney J.E. Influenza vaccine responses in older adults. Ageing Res Rev 2011, 10:379-388.
4. McElhaney J.E., Effros R.B. Immunosenescence: what does it mean to health outcomes in older adults. Curr Opin Immunol 2009, 21:418-424.
5. Simonsen L., Taylor R.J., Viboud C., Miller M.A., Jackson L.A. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007, 7:658-666.
6. Targonski P.V., Jacobson R.M., Poland G.A. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007, 25:3066-3069.
7. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995, 123:518-527.
8. Simonsen L., Clarke M.J., Schonberger L.B., Arden N.H., Cox N.J., Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998, 178:53-60.
9. Frasca D., Diaz A., Romero M., Mendez N.V., Landin A.M., Blomberg B.B. Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season. Immun Ageing 2013, 10:14.
10. Frasca D., Diaz A., Romero M., Phillips M., Mendez N.V., Landin A.M., et al. Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int Immunol 2012, 24:175-182.
11. Khurana S., Frasca D., Blomberg B., Golding H. AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans. PLoS Pathog 2012, 8:e1002920.
12. Khurana S., Verma N., Talaat K.R., Karron R.A., Golding H. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2012, 205:610-620.
13. Sasaki S., Sullivan M., Narvaez C.F., Holmes T.H., Furman D., Zheng N.Y., et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Investig 2011, 121:3109-3119.
14. Verma N., Dimitrova M., Carter D.M., Crevar C.J., Ross T.M., Golding H., et al. Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children. J Virol 2012, 86:5515-5522.
15. Bernstein E., Kaye D., Abrutyn E., Gross P., Dorfman M., Murasko D.M. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999, 17:82-94.
16. Frasca D., Diaz A., Romero M., Landin A.M., Phillips M., Lechner S.C., et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 2010, 28:8077-8084.
17. McElhaney J.E., Beran J., Devaster J.M., Esen M., Launay O., Leroux-Roels G., et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013, 13:485-496.
18. Murasko D.M., Bernstein E.D., Gardner E.M., Gross P., Munk G., Dran S., et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002, 37:427-439.
19. van Essen G.A., Beran J., Devaster J.M., Durand C., Duval X., Esen M., et al. Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza Other Respir Viruses 2014, 8:452-462.
20. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
21. Frasca D., Diaz A., Romero M., Mendez N.V., Landin A.M., Ryan J.G., et al. Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine 2013, 31:3603-3610.
22. Sasaki S., He X.S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3:e2975.
23. Pritz T., Lair J., Ban M., Keller M., Weinberger B., Krismer M., et al. Plasma cell numbers decrease in bone marrow of old patients. Eur J Immunol 2015, 45:738-746.
24. Kaml M., Weiskirchner I., Keller M., Luft T., Hoster E., Hasford J., et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006, 24:6808-6811.
25. Frasca D., Diaz A., Romero M., Landin A.M., Blomberg B.B. High TNF-alpha levels in resting B cells negatively correlate with their response. Exp Gerontol 2014, 54:116-122.
26. Frasca D., Diaz A., Romero M., Landin A.M., Blomberg B.B. Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine. Vaccine 2015, 33:1433-1439.
27. Frasca D., Diaz A., Romero M., Ferracci F., Blomberg B.B. Micro-RNAs miR-155 and miR-16 decrease AID and E47 in B cells from elderly individuals. J Immunol 2015, 195:2134-2140.
28. Frasca D., Ferracci F., Diaz A., Romero M., Lechner S., Blomberg B.B. Obesity decreases B cell responses in young and elderly individuals. Obesity 2016, 24:615-625.
29. Faenzi E., Zedda L., Bardelli M., Spensieri F., Borgogni E., Volpini G., et al. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine 2012, 30:4086-4094.
30. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
31. Cox R.J., Brokstad K.A., Zuckerman M.A., Wood J.M., Haaheim L.R., Oxford J.S. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994, 12:993-999.
32. Frasca D., Landin A.M., Lechner S.C., Ryan J.G., Schwartz R., Riley R.L., et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol 2008, 180:5283-5290.
33. Goenka R., Scholz J.L., Naradikian M.S., Cancro M.P. Memory B cells form in aged mice despite impaired affinity maturation and germinal center kinetics. Exp Gerontol 2014, 54:109-115.
34. Skowronski D.M., Tweed S.A., De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant. J Infect Dis 2008, 197:490-502.
35. Shaffer A.L., Lin K.I., Kuo T.C., Yu X., Hurt E.M., Rosenwald A., et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002, 17:51-62.
36. Andrews S.F., Kaur K., Pauli N.T., Huang M., Huang Y., Wilson P.C. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response. J Virol 2015, 89:3308-3317.
37. Pyhala R., Kumpulainen V., Alanko S., Forsten T. HI antibody kinetics in adult volunteers immunized repeatedly with inactivated trivalent influenza vaccine in 1990-1992. Vaccine 1994, 12:947-952.
38. de Bruijn I.A., Remarque E.J., Jol-van der Zijde C.M., van Tol M.J., Westendorp R.G., Knook D.L. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999, 179:31-36.
39. Rinaldi S., Zangari P., Cotugno N., Manno E.C., Brolatti N., Castrucci M.R., et al. Antibody but not memory B-cell responses are tuned-down in vertically HIV-1 infected children and young individuals being vaccinated yearly against influenza. Vaccine 2014, 32:657-663.